AU2021252821A1 - Methods and means for modifying hemodynamics in infections - Google Patents

Methods and means for modifying hemodynamics in infections Download PDF

Info

Publication number
AU2021252821A1
AU2021252821A1 AU2021252821A AU2021252821A AU2021252821A1 AU 2021252821 A1 AU2021252821 A1 AU 2021252821A1 AU 2021252821 A AU2021252821 A AU 2021252821A AU 2021252821 A AU2021252821 A AU 2021252821A AU 2021252821 A1 AU2021252821 A1 AU 2021252821A1
Authority
AU
Australia
Prior art keywords
peptide
aqgv
patients
infection
lung
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021252821A
Other languages
English (en)
Inventor
Eric Claassen
Johan Renes
Gert Wensvoort
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotempt BV
Original Assignee
Biotempt BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotempt BV filed Critical Biotempt BV
Publication of AU2021252821A1 publication Critical patent/AU2021252821A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2021252821A 2020-04-06 2021-04-06 Methods and means for modifying hemodynamics in infections Pending AU2021252821A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063005999P 2020-04-06 2020-04-06
US63/005,999 2020-04-06
US202063045737P 2020-06-29 2020-06-29
US63/045,737 2020-06-29
US202063085771P 2020-09-30 2020-09-30
US63/085,771 2020-09-30
PCT/NL2021/050223 WO2021206547A1 (en) 2020-04-06 2021-04-06 Methods and means for modifying hemodynamics in infections

Publications (1)

Publication Number Publication Date
AU2021252821A1 true AU2021252821A1 (en) 2022-11-24

Family

ID=75581581

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021252821A Pending AU2021252821A1 (en) 2020-04-06 2021-04-06 Methods and means for modifying hemodynamics in infections

Country Status (9)

Country Link
US (1) US20230241155A1 (https=)
EP (1) EP4132556A1 (https=)
JP (2) JP2023521744A (https=)
KR (1) KR20230003495A (https=)
AU (1) AU2021252821A1 (https=)
CA (1) CA3174852A1 (https=)
CO (1) CO2022015018A2 (https=)
MX (1) MX2022012506A (https=)
WO (1) WO2021206547A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4021481A1 (en) * 2019-08-30 2022-07-06 Biotempt B.V. Q-er peptide
AU2021354766A1 (en) * 2020-09-30 2023-05-11 Biotempt B.V. Autophagy-inhibiting peptide and organic acid salt thereof addressing issues of vascular permeability
WO2025191033A1 (en) 2024-03-13 2025-09-18 Biotempt B.V. Per-operative treatment of post-operative complications (poc)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ542791A (en) * 2003-04-08 2008-04-30 Biotempt Bv Compositions for mucosal and oral administration comprising HCG fragments
EP4021481A1 (en) * 2019-08-30 2022-07-06 Biotempt B.V. Q-er peptide
CA3152346A1 (en) * 2019-09-30 2021-04-08 Roelof Peter Pickkers Methods of treatment for modifying hemodynamics

Also Published As

Publication number Publication date
JP2026027378A (ja) 2026-02-18
MX2022012506A (es) 2023-01-16
EP4132556A1 (en) 2023-02-15
WO2021206547A1 (en) 2021-10-14
KR20230003495A (ko) 2023-01-06
JP2023521744A (ja) 2023-05-25
CA3174852A1 (en) 2021-10-14
US20230241155A1 (en) 2023-08-03
CO2022015018A2 (es) 2022-10-31

Similar Documents

Publication Publication Date Title
JP2026027378A (ja) 感染症における血行動態を変更する為の方法及び手段
Warnock et al. Blood pressure and amiloride-sensitive sodium channels in vascular and renal cells
EP1723962A1 (en) Use of inhibitors of the renin-angiotensin system for the treatment of lung injuries
CN109010801A (zh) 治疗心力衰竭的组份和方法
Wevers et al. Renin–angiotensin system in human coronavirus pathogenesis
US20220370543A1 (en) Methods of treatment for modifying hemodynamics
CN106061493A (zh) 血管紧张素ii单独或以组合方式用于治疗低血压
CN109529028A (zh) 在感染的治疗和预防中的神经酰胺水平
AU2020337111A1 (en) Q-ER peptide
US20240016882A1 (en) Autophagy-inhibiting peptide and organic acid salt thereof addressing issues of vascular permeability
US20210369665A1 (en) Methods of treating viral infection using protease inhibitors
US20240325496A1 (en) Cxc chemokine agonists and antagonists in covid-19 disease and diagnostic assays
US20210052701A1 (en) Methods of Treating Vascular Leakage Using CXCL12 Peptides
WO2021189038A1 (en) Ang 1-7 as a therapeutic for coronavirus
Hamdi et al. The human-COVID-19 tango: connecting the dots
US20240025949A1 (en) Beta-Arrestin Effectors and Compositions and Methods of Use Thereof
WO2016196750A1 (en) Beta-arrestin effectors and compositions and methods of use thereof
CN108553636A (zh) 蛋白c在制备防治肺动脉高压病药物中的应用
WO2021216529A1 (en) β-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF
HK40128284A (zh) 急性呼吸衰竭的治疗
KR20230022876A (ko) 바이러스성 내피염 치료용 bbeta-15-42
Gupta Metalloprotease and endothelin-mediated signaling mechanisms in sepsis and related cardiovascular disorders
CN102782129A (zh) 药物组合物
Varagic Articles in PresS. Am J Physiol Heart Circ Physiol (February 12, 2016). doi: 10.1152/ajpheart. 00833.2015
Moayeri et al. Bacillus anthracis Edema Toxin Inhibits Hypoxic Pulmonary Vasoconstriction 1 via Edema Factor and cAMP Mediated Mechanisms in Isolated Perfused Rat Lungs 2 3 Xizhong Cui1, Jeffrey Wang1, Yan Li1, Zoe G. Couse1, Thomas F. Risoleo1, 4 Mahtab Moayeri2, Stephen H. Leppla2, Daniela Malide3, Zu-Xi Yu3, and Peter Q. Eichacker1 5